We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 82.50 | 80.00 | 85.00 | 82.50 | 82.50 | 82.50 | 5,234 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Computers | 1.03M | -2.92M | -0.2188 | -3.77 | 11M |
Date | Subject | Author | Discuss |
---|---|---|---|
30/7/2020 16:17 | Well done Tom. Ignore the ups and downs now and the hourly gyration. I’ll be holding my shares for a very long time to come! | petekand | |
30/7/2020 16:15 | Trigger happy sellers no doubt had alert set up....should see buyers who haven't seen the news yet coming in and then who knows what news to come. | monkey puzzle | |
30/7/2020 16:12 | What a drop from such an instant rise! | sonie01 | |
30/7/2020 16:12 | If believed in this over last few months / year ... direction heading and just waiting for real validation and traction of product then daft to sell now. NHSX is the real validation and fully expect substantial sales to follow. Think Bleepa is on it's way... | meganxmas | |
30/7/2020 16:10 | Dnt be left holding | newtoaim | |
30/7/2020 16:09 | I'm guessing day traders selling that's what bought the price down | sonie01 | |
30/7/2020 15:57 | Trust them to announce that while I'm hanging out my washing. | lr2 | |
30/7/2020 15:56 | Predictions? | sonie01 | |
30/7/2020 15:55 | NHSx Clinical Communication Tool Framework endorses Bleepa and provides route to payment The Directors believe that as the only CE marked product for digital patient imaging on the framework Bleepa is the only provider that can deliver digital imaging as part of the communication service | ged5 | |
30/7/2020 15:52 | That is an excellent step ! | meganxmas | |
30/7/2020 15:51 | Onto the NHSx system now | sonie01 | |
30/7/2020 15:07 | Looks like a buy. | lr2 | |
30/7/2020 14:57 | 1.4m trade... | monkey puzzle | |
29/7/2020 20:06 | Interesting, 25% rise, quiet BB so the herd not involved. Quite a few chunky buys. Hopefully TO about to become a hero for us LTH. | ducatiman | |
29/7/2020 14:19 | Volume approaching 12m | brasso3 | |
29/7/2020 14:11 | And a second one. | lr2 | |
29/7/2020 14:11 | I do believe they have a much better offering than the others closely tied to true PACS. Nice move. Hopefully someone knows something. | petekand | |
29/7/2020 14:05 | Price monitoring extension. | lr2 | |
29/7/2020 13:24 | We don’t actually know how important the CE mark is in the selling process. Imo it should not be the thing driving sales, unless there is serious competition from equivalent products and the only wsy to differentiate Bleepa is to say ‘but ours has a CE mark’. Fdbk should surely be convincing prospects that they have a better offering, because a CE mark could be got by the competition and then, if you haven’t sold your benefits properly, there’s no foundation. | yump | |
29/7/2020 13:21 | Nearly 10m volume so far today. A few more days like this will be nice. | brasso3 | |
29/7/2020 11:35 | Thanks LR2. With over 16m shares in the last placing, I'm not surprised he's tweeting. Like us, he sees the importance of the CE mark attached to Bleepa. I think he's stalking me though. He also tweets about another company I have shares in. The common factor is young energetic bright management. If you take Bleepa as being a young company after the most recent re-invention and a company with plenty of potential then that's also a common factor. | ged5 | |
29/7/2020 11:31 | Another million gone through. 29-Jul-20 10:12:17 1.140p 1,000,000 Unknown* 1.10p 1.15p £11.40k | lr2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions